Welcome to our dedicated page for Evaxion AS SEC filings (Ticker: EVAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Evaxion A/S (EVAX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily filed as Form 6-K current reports and other registration statements. As a foreign private issuer listed on the Nasdaq Capital Market, Evaxion files under Form 20-F and uses Form 6-K to furnish press releases and key corporate information to investors.
Evaxion’s recent 6-K filings frequently incorporate press releases that describe clinical and preclinical data from its AI-Immunology™ powered vaccine programs, including oncology candidates such as EVX-01 and EVX-04 and infectious disease programs like EVX-V1 and EVX-B2. These filings can give investors additional context on trial design, data readouts, and scientific presentations at major conferences.
Other 6-K reports document capital structure changes, such as amendments to the Articles of Association following share capital increases from investor warrant exercises. These filings outline new share issuances, nominal capital changes and related cash considerations, helping readers understand dilution, equity financing and the evolution of Evaxion’s capital base.
Evaxion also uses 6-Ks to furnish business updates and financial results, including quarterly performance, cash runway commentary, partnership income from out-licensed assets like EVX-B3, and information on capital market activities. In addition, the company’s registration statements on Forms F-1, F-3 and S-8 are referenced in 6-Ks through incorporation by reference language, indicating how new disclosures become part of existing prospectuses.
On Stock Titan, these filings are presented with AI-powered summaries that highlight the main points of each document, from scientific milestones to financing transactions. Users can quickly scan new 6-K submissions, identify filings related to clinical data, capital raises or governance changes, and then dive into the full text for deeper analysis. This page is a central resource for tracking EVAX’s regulatory reporting, capital markets activity and the formal record of its AI-Immunology™ platform and pipeline developments.
Evaxion A/S filed a Form 6-K furnishing a press release dated October 8, 2025 that announces the company has expanded its AI-Immunology™ platform by adding an automated vaccine design module. The filing states the press release is provided as Exhibit 99.1 and that this Form 6-K is incorporated by reference into several of the company's registration statements, to the extent not superseded by later filings. No financial metrics, commercialization milestones, timeline, or technical performance data for the new module are included in the filing.
Evaxion A/S disclosed that it will present new biomarker data for its AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting. The Form 6-K furnishes a press release as Exhibit 99.1 and incorporates this report by reference into several of the company’s registration statements. The filing contains no financial results, trial endpoints, patient counts, or detailed data—only the announcement of the planned presentation. Investors are informed of the forthcoming scientific disclosure but must look to the press release or the SITC presentation itself for substantive clinical or biomarker findings.
Evaxion A/S furnished a press release dated September 25, 2025 announcing that it has out-licensed its vaccine candidate EVX-B3 to MSD. The Form 6-K states the press release is filed as Exhibit 99.1 and that this report is incorporated by reference into several of Evaxion's registration statements, including Forms S-8, F-3 and multiple F-1 filings. The filing provides notice of the transaction but includes no financial terms, milestone schedules, or operational details within this report.
Evaxion A/S furnished a Form 6-K reporting that it issued a press release titled "Evaxion to present at several conferences during the second half of 2025" and furnished that press release as Exhibit 99.1 to the report. The company states this Form 6-K is incorporated by reference into multiple registration statements, including Forms S-8, F-3 and several Form F-1 filings, such that the press release and related disclosure become part of those registration statements to the extent not superseded. The report is signed on behalf of the registrant by Birgitte Rønø, Interim Chief Executive Officer.
Evaxion A/S, a clinical-stage TechBio company developing AI-Immunology powered vaccines, furnished a Form 6-K for August 2025. The filing mainly reports that on August 14, 2025 the company issued a press release titled "Evaxion announces business update and second quarter 2025 financial results," which is included as Exhibit 99.1. The Form 6-K is also incorporated by reference into multiple existing registration statements on Forms S-8, F-3 and F-1, allowing the information in this report to be used in those offering documents.
Evaxion Biotech A/S submitted a Form 6-K as a foreign private issuer, providing investors with updated information on its business. The filing states that the company has furnished unaudited condensed consolidated interim financial statements and a management discussion and analysis for the fiscal quarter ended June 30, 2025. These materials are included as exhibits and are also incorporated by reference into several of Evaxion’s existing registration statements. The report is signed by the company’s Chief Executive Officer, Birgitte Rønø, and Chief Financial Officer, Thomas Frederik Schmidt, confirming management’s authorization of this quarterly disclosure.
Evaxion A/S, a clinical-stage TechBio company using AI-Immunology, furnished a press release announcing it will provide a business update and publish its second-quarter 2025 financial results on August 14, 2025. The Form 6-K states the press release is furnished as Exhibit 99.1 to the filing.
The filing itself contains no financial figures, operational metrics, or transaction details; it serves to notify investors of the timing and availability of the forthcoming update and results announcement.
Evaxion A/S (NASDAQ: EVAX) filed a Form 6-K on 11 July 2025 to furnish a press release announcing that the Company has finalized an agreement with the European Investment Bank (EIB) to convert existing debt into equity. The press release, provided as Exhibit 99.1, is the only substantive disclosure contained in the filing. No additional terms, financial amounts, or timing details are included in the 6-K.